Company intelligence / Profile preview
ARC Therapies
Shinjuku, Tokyo Prefecture, Japanarctherapies.inc ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ARC Therapies has discovered the YB328 bacterial strain linked to enhanced responses to immune checkpoint inhibitors in cancer patients. Initial murine model studies suggest potent anti-tumor immune activation; the company is advancing ARC0812 toward preclinical and human clinical trials, with studies ongoing to evaluate efficacy and administration methods.
- Therapeutic areas
- Oncology
- Modalities
- Live biotherapeutic product therapyMicrobial therapyImmune adjuvant (as a functional class)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
National Cancer Center Japan (originating research/facility)collaborating with lead scientists from NCC
Beyond the preview
Go deeper on ARC Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC Therapies.